About AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) AREXVY contains recombinant RSV glycoprotein F stabilized in the prefusion conformation (RSVPreF3). This antigen is combined with GSK ...

Ziresovir is the first antiviral to demonstrate significant clinical efficacy and long-term respiratory benefits in hospitalized infants under six months of age with respiratory syncytial virus.

Last year people aged between 75 and 79 and pregnant women were offered a first-of-its-kind jab against respiratory syncytial virus (RSV). The bug is responsible for some 50,000 hospitalisations ...

Respiratory Syncytial ... the virus is actually just as worrisome in older adults. In fact, while more than 2 million children under age 5 make an RSV-related outpatient visit each year with ...

Thousands more Brits will receive vaccinations this year against a potentially ... and the 8,000 deaths linked to respiratory syncytial virus (RSV) every year. While many who come into contact ...

Researchers from GlaxoSmithKline have reported that a single dose of the RSV vaccine, Arexvy (RSVPreF3 OA), provides effective protection against respiratory syncytial virus-related lower ...

(Reuters) -Infant hospitalizations due to respiratory syncytial virus (RSV) infections in the United States dropped as much as 43% last year compared to previous years, following the widespread ...

On Wednesday, the Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of respiratory syncytial virus (RSV ... each year in adults aged 50-64 years ...

It earned approval for a vaccine for the respiratory syncytial virus (RSV), mRESVIA, while it aced phase 3 studies for a combination coronavirus/influenza vaccine that could earn the green light ...

On top of that, the company's second approved product -- a respiratory syncytial virus (RSV ... Bringing a vaccine to market in less than a year First, let's summarize Moderna's story so far.

Pfizer has been awarded breakthrough status from the FDA for its respiratory syncytial virus (RSV ... also expected in the first half of this year, around the same time as GSK is expecting ...